Weaver C. Barksdale & Associates’s Idexx Laboratories IDXX Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-82	Closed	-$10K	–	532
2016 Q4	$10K	Buy	82 +9	+12%	+$1.03K	0.02%	281
2016 Q3	$8K	Sell	73 -19	-21%	-$2K	0.01%	301
2016 Q2	$9K	Hold	92	–	–	0.02%	262
2016 Q1	$7K	Hold	92	–	–	0.01%	335
2015 Q4	$7K	Buy	92 +6	+7%	+$428	0.01%	321
2015 Q3	$6K	Sell	86 -17	-17%	-$1.22K	﹤0.01%	343
2015 Q2	$7K	Buy	103 +19	+23%	+$1.31K	0.01%	330
2015 Q1	$6K	Hold	84	–	–	﹤0.01%	362
2014 Q4	$6K	Sell	84 -24	-22%	-$1.68K	﹤0.01%	345
2014 Q3	$6K	Buy	108 +12	+13%	+$759	﹤0.01%	335
2014 Q2	$6K	Hold	96	–	–	﹤0.01%	348
2014 Q1	$6K	Sell	96 -12	-11%	-$715	0.01%	345
2013 Q4	$6K	Hold	108	–	–	0.01%	349
2013 Q3	$5K	Sell	108 -10	-8%	-$481	﹤0.01%	379
2013 Q2	$5K	Buy	+118	New	+$5.16K	﹤0.01%	368

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

ACM

Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Weaver C. Barksdale & Associates's IDXX Position: Q1 2017 in Review

Weaver C. Barksdale & Associates sold out of Idexx Laboratories (IDXX) in Q1 2017, closing a stake of 82 shares — an estimated $10K sold.

Weaver C. Barksdale & Associates first reported a position in IDXX in Q2 2013 and held it in 15 quarters. The position peaked at $10K in Q4 2016. 542 funds tracked by Wall St. Rank hold IDXX as of Q1 2017.

Weaver C. Barksdale & Associates reported no remaining Idexx Laboratories position as of Q1 2017 after selling out during the quarter.
Weaver C. Barksdale & Associates sold 82 Idexx Laboratories shares in Q1 2017, an estimated $10K.
Weaver C. Barksdale & Associates first reported a position in Idexx Laboratories in Q2 2013 and held it in 15 quarters.
Weaver C. Barksdale & Associates's Idexx Laboratories position peaked at $10K in Q4 2016.
542 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2017.

Based on Weaver C. Barksdale & Associates's 13F filing for Q1 2017, filed 7 Apr 2017.